PMGC Holdings Inc. (ELAB) stock
ELABNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 4/3095% below fair value
$1.47−0.01 (-0.68%)
Close on Nov 18, 2026Market cap $1.31MP/E –Yield –
PMGC revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
PMGC's revenue for the twelve months ending Sep 30, 2026 was $4.82M. For fiscal 2025 it was $590.08K, down 65.5% from the year before.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $590.08K | -65.5% |
| FY2023 | Dec 31, 2023 | $1.71M | +123.5% |
| FY2022 | Dec 31, 2022 | $766.28K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $2.53M | +784.9% |
| Q2 FY2026 | Jun 30, 2026 | $1.31M | +147.7% |
| Q1 FY2026 | Mar 31, 2026 | $681.99K | +12.6% |
| Q4 FY2025 | Dec 31, 2025 | $304.14K | -50.5% |
| Q3 FY2025 | Sep 30, 2025 | $285.95K | -59.1% |
| Q3 FY2024 | Sep 30, 2024 | $527.48K | -4.9% |
| Q2 FY2024 | Jun 30, 2024 | $605.53K | +91.3% |
| Q1 FY2024 | Mar 31, 2024 | $614.56K | +330.3% |
| Q4 FY2023 | Dec 31, 2023 | $698.59K | -99.8% |
| Q3 FY2023 | Sep 30, 2023 | $554.65K | – |
| Q2 FY2023 | Jun 30, 2023 | $316.53K | – |
| Q1 FY2023 | Mar 31, 2023 | $142.82K | – |
| Q3 FY2022 | Sep 30, 2022 | $432.12M | – |
See a number that looks wrong?